Advertisement

European Journal of Pediatrics

, Volume 148, Issue 4, pp 300–303 | Cite as

Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major

  • M. Bozzola
  • J. Argente
  • M. Cisternino
  • A. Moretta
  • A. Valtorta
  • I. Biscaldi
  • M. Donnadieu
  • D. Evain-Brion
  • F. Severi
Hematology/Oncology

Abstract

The effect of long-term human chorionic gonadotropin (HCG) therapy on the linear growth and biological growth parameters was studied in six thalassaemic boys aged 14.5–15.5 years old with hypogonadotropic hypogonadism. A significant (P<0.001) increase in growth velocity (from 3.3±0.3 to 7.6±0.6 cm/year) was found after 6–12 months of therapy, without acceleration of bone age. A striking improvement in pubertal development was observed. The treatment significantly increased growth hormone (GH) response to l-dopa administration (P<0.025) as well as sleep GH secretion (P<0.025). Serum growth factors, evaluated as thymidine activity during deep sleep, increased (P<0.001), but somatomedin C (Sm-C) levels did not. Prior to treatment, baseline and peak values of plasma growth hormone releasing hormone (GH-RH) following l-dopa were low. After HCG therapy, GH-RH response to l-dopa increased significantly (from 9.2±5.6 to 20.2±6.2 pg/ml; P<0.05), but remained (P<0.001) lower than in normal prepubertal children. This study suggests that in thalassaemia major an impaired GH-RH release can be observed, in addition to the described alteration in Sm-C generation.

Key words

Human chorionic gonadotropin Thalassaemia major Growth velocity 

Abbreviations

LH

luteinising hormone

FSH

follicle stimulating hormone

HCG

human chorionic gonadotropin

GH

growth hormone

GH-RH

growth hormone releasing hormone

GnRH

gonadotropin releasing hormone

TA

thymidine activity

Sm-C

somatomedin C

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Argente J, Evain-Brion D, Munoz-Villa A, Garnier P, Hernandez M, Donnadieu M (1986) Relationship of plasma growth hormone-releasing hormone levels to pubertal changes. J Clin Endocrinol Metab 63:680–682Google Scholar
  2. 2.
    Argente J, Evain-Brion D, Donnadieu M, Garnier P, Vaudry H, Job JC (1987) Impaired response of growth hormone-releasing hormone (GHRH) measured in plasma after l-dopa stimulation in patients with idiopatic delayed puberty. Acta Paediatr Scand 76: 266–270Google Scholar
  3. 3.
    Bannerman RM, Keutsch G, Birnbaum MD, Vance VK, Vaughan S (1967) Thalassemia intermedia with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyria. Am J Med 42:476–479Google Scholar
  4. 4.
    Barry M, Flynn DM, Letsky EA, Risdon RA (1974) Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J II:16–20Google Scholar
  5. 5.
    Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti V, Piga A (1985) Growth and sexual maturation in thalassemia major. J Pediatr 106:150–155Google Scholar
  6. 6.
    Bozzola M, Cisternino M, Ghini M, Berbenni A, Ciceri R, Valtorta A, Severi F (1986) Effetti in vivo ed in vitro del testosterone su un' attività serica di crescita misurata come incorporazione di 3H-timidina in linfociti umani attivati. Riv Ital Pediatr 12:234–238Google Scholar
  7. 7.
    Canale VC, Steinherz P, New M, Erlandson M (1974) Endocrine function in thalassaemia major. Ann NY Acad Sci 232:333–339Google Scholar
  8. 8.
    Cavallo L, Montone A, Altomare M, Licciulli M, Pascazio A, Schettini F (1981) Pituitary thyroidal function in children with β-thalassemia major. Acta Endocrinol (Copenh) 96:59–64Google Scholar
  9. 9.
    Chihara K, Kashio Y, Kita T, Okimura Y, Kaji H, Abe H, Fujita T (1986) l-Dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 62: 466–473Google Scholar
  10. 10.
    Colombo A, Larizza D, Garibaldi E, Bozzola M, Gasparoni MC, Peretti L (1977) Crescita ed alcuni parametri endocrinologici con particolare riferimento al GH nella Thalassemia major. Minerva Pediatr 29:1235–1239Google Scholar
  11. 11.
    De Luca F, Melluso R, Sobbrio G, Canfora G, Trimarchi F (1980) Thyroid function in thalassemia major. Arch Dis Child 55:389–352Google Scholar
  12. 12.
    Donnadieu M, Evain-Brion D, Tonon MC, Vaudry H, Job JC (1985) Variations of plasma growth hormone (GH)-releasing factor levels during GH stimulation tests in children. J Clin Endocrinol Metab 60:1132–1134Google Scholar
  13. 13.
    Evain-Brion D, Donnadieu M, Liapi C, Argente J, Tonon MC, Garnier P, Job JC (1986) Plasma growth hormone-releasing factor levels in children: physiological and pharmacologically induced variations. Horm Res 24:116–120Google Scholar
  14. 14.
    Flynn DM, Fairney A, Jackson D, Clayton B (1976) Hormonal changes in thalassemia major. Arch Dis Child 51:828–836Google Scholar
  15. 15.
    Guidoux S, Schimpff RM, Evain-Brion D, Garnier P, Job JC (1985) Effect of gonadotrophin-induced elevation of serum testosterone upon somatomedin-C and serum thymidine activity in children. Horm Res 21:75–82Google Scholar
  16. 16.
    Herington AC, Werther GA, Matthews RN, Burger HG (1981) Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major. J Clin Endocrinol Metab 52:393–398Google Scholar
  17. 17.
    Johnston FE, Hertzog KP, Malina RM (1966) Longitudinal growth in thalassemia major. Am J Dis Child 112:396–401Google Scholar
  18. 18.
    Kattamis C, Touliatos N, Haidos S, Matsaniotis N (1970) Growth of children with thalassemia: effect of different transfusion regimes. Arch Dis Child 54:502–505Google Scholar
  19. 19.
    Kaye SB, Owen M (1978) Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. Br Med J I:342–343Google Scholar
  20. 20.
    Kletzky OA, Costin G, Marrs RP, Bernstein G, March CM, Mishell DR (1979) Gonadotropin insufficiency in patients with thalassemia maior. J Clin Endocrinol Metab 48:901–905Google Scholar
  21. 21.
    Kuo B, Zaino E, Roginsky MS (1968) Endocrine function in thalassemia major. J Clin Endocrinol Metab 28:805–808Google Scholar
  22. 22.
    Lassman MN, O'Brien RT, Pearson HA, Wise JK, Donabedian RE, Felig P, Genel M (1974) Endocrine evaluation in thalassemia major. Ann NY Acad Sci 232:270–274Google Scholar
  23. 23.
    Logothetis J, Loewenson RB, Augousteki O, Economidou J, Constantoulakis M (1972) Body growth in Cooley's anemia (homozygous beta-thalassemia) with a correlative study as to other aspects of the illness in 138 cases. Pediatrics 50:92–99Google Scholar
  24. 24.
    Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Rassu S, Milia AF (1984) Endocrine functioning in multitransfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 58:667–670Google Scholar
  25. 25.
    McIntosh N (1976) Endocrinopathy in thalassemia major. Arch Dis Child 51:195–201Google Scholar
  26. 26.
    Modell B (1977) Total management of thalassemia major. Arch Dis Child 52:489–500Google Scholar
  27. 27.
    Pintor C, Cella SG, Manso P, Corda R, Dessi C, Locatelli V, Muller EE (1986) Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 62:263–267Google Scholar
  28. 28.
    Saenger P, Schwartz E, Markenson AL, Graziano JH, Levine LS, New MI, Hilgartner MV (1980) Depressed serum somatomedin activity in β-thalassemia. J Pediatr 96:214–218Google Scholar
  29. 29.
    Spiliotis BE, August GP, Wellington H, Sonis W, Mendelson W, Bercu BB (1984) Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA 251:2023–2030Google Scholar
  30. 30.
    Thiériot-Prévost G, Schimpff RM (1980) Mesure de l'incorporation de thymidine tritiée dans le lymphocyte activé et activité somatomédine du sérum. C R Acad Sci [III] 290:527–530Google Scholar
  31. 31.
    Werther GA, Matthews RN, Burger HG, Herington AC (1981) Lack of response of nonsuppressible insulin-like activity to short term administration of human growth hormone in thalassemia major. J Clin Endocrinol Metab 53:806–809Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • M. Bozzola
    • 1
  • J. Argente
    • 2
  • M. Cisternino
    • 1
  • A. Moretta
    • 1
  • A. Valtorta
    • 1
  • I. Biscaldi
    • 1
  • M. Donnadieu
    • 2
  • D. Evain-Brion
    • 2
  • F. Severi
    • 1
  1. 1.Paediatric Clinic, 2nd ChairUniversity of PaviaPaviaItaly
  2. 2.INSERM U188ParisFrance

Personalised recommendations